Articles related to PEDIATRIC CANCER
Brentuximab Vedotin Gets New Indication
The approval for the treatment of pediatric patients aged 2 years and older with previously untreated high-risk classic Hodgkin lymphoma (HL) was based on the AHOD1331 phase 3 study, which examined the effects of brentuximab vedotin (Adcetris, Seagen) in combination with the dose-intensive chemotherapy regimen AVE-PC (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide). Results showed that patients who received the AVE-PC combination had better event-free survival than those who received ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide). Patients experienced a 59% decrease in their risk of death, second cancer, or disease progression.
Oncology, Medical November 28th 2022
Management of Relapsed or Progressive Pediatric Low-Grade Glioma
Amar Gajjar, MD, who serves as the co-chair of the oncology department and chair of the pediatric medicine department at St. Jude Children’s Research Hospital in Memphis, Tennessee, answers questions from our friends at Cancer Therapy Advisor. Proton therapy, conventional chemotherapy, targeted therapies, and observed glioma progression are all topics covered by Dr. Gajjar when talking about treatment options for pediatric low-grade gliomas (pLGG) that have relapsed or progressed.
Oncology, Medical November 14th 2022
FDA Committee Unanimously Rejects 131-I-Omburtamab for Neuroblastoma
The FDA Oncologic Drugs Advisory Committee (ODAC) unanimously decided on October 28 that there is insufficient evidence to support the claim that the pediatric oncology drug 131-I-omburtamab improves overall survival. A radiolabeled antibody, 131-I-omburtamab was created to treat central nervous system/leptomeningeal (CNS/LM) metastases in pediatric patients with neuroblastoma.
Oncology, Medical November 7th 2022
New Approaches to T-Cell Acute Lymphoblastic Leukemia
Perelman School of Medicine’s David Teachey, MD, reviews outcomes and implications from two recent Children’s Oncology Group trials and describes current research with daratumumab and CAR T-cell therapy.
Oncology, Medical May 18th 2022
Children’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
Patients with T-LL had significantly improved EFS and OS with bortezomib on the AALL1231 backbone. Systemic therapy intensification allowed elimination of CRT in more than 90% of patients with T-ALL without excess relapse. There was no difference in rates of receiving CRT.
Oncology, Medical March 22nd 2022
Synovial Sarcoma in Children, Adolescents, and Young Adults
This Original Report from the Journal of Clinical Oncology based on the ARST0332 trial concludes: “The risk-based treatment strategy used in ARST0332 produced favorable outcomes in patients with nonmetastatic synovial sarcoma (SS) relative to historical controls despite using RT less frequently and at lower doses. The outcome for metastatic SS remains unsatisfactory and new therapies are urgently needed.”
Internal Medicine December 21st 2021